Market capitalization | $491.41m |
Enterprise Value | $260.83m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.71 |
P/S ratio (TTM) P/S ratio | 10.75 |
P/B ratio (TTM) P/B ratio | 1.76 |
Revenue growth (TTM) Revenue growth | 7.50% |
Revenue (TTM) Revenue | $45.71m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
12 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
12 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 46 46 |
8%
8%
|
|
Gross Profit | 42 42 |
19%
19%
|
|
EBITDA | -116 -116 |
43%
43%
|
EBIT (Operating Income) EBIT | -117 -117 |
43%
43%
|
Net Profit | -104 -104 |
3%
3%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Jay Duker |
Employees | 121 |
Founded | 1987 |
Website | www.eyepointpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.